Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.58
PDLI's Cash to Debt is ranked higher than
53% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. PDLI: 0.58 )
PDLI' s 10-Year Cash to Debt Range
Min: 0.25   Max: No Debt
Current: 0.58

Equity to Asset 0.41
PDLI's Equity to Asset is ranked higher than
58% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PDLI: 0.41 )
PDLI' s 10-Year Equity to Asset Range
Min: -1.93   Max: 0.98
Current: 0.41

-1.93
0.98
Interest Coverage 16.39
PDLI's Interest Coverage is ranked higher than
53% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PDLI: 16.39 )
PDLI' s 10-Year Interest Coverage Range
Min: 1.29   Max: 9999.99
Current: 16.39

1.29
9999.99
F-Score: 3
Z-Score: 4.60
M-Score: 40.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 92.47
PDLI's Operating margin (%) is ranked higher than
100% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. PDLI: 92.47 )
PDLI' s 10-Year Operating margin (%) Range
Min: -194.42   Max: 94.93
Current: 92.47

-194.42
94.93
Net-margin (%) 58.03
PDLI's Net-margin (%) is ranked higher than
98% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. PDLI: 58.03 )
PDLI' s 10-Year Net-margin (%) Range
Min: -215.32   Max: 59.72
Current: 58.03

-215.32
59.72
ROE (%) 153.79
PDLI's ROE (%) is ranked higher than
100% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. PDLI: 153.79 )
PDLI' s 10-Year ROE (%) Range
Min: -35.5   Max: 1166.18
Current: 153.79

-35.5
1166.18
ROA (%) 44.09
PDLI's ROA (%) is ranked higher than
99% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. PDLI: 44.09 )
PDLI' s 10-Year ROA (%) Range
Min: -17.78   Max: 77.05
Current: 44.09

-17.78
77.05
ROC (Joel Greenblatt) (%) 18680.62
PDLI's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. PDLI: 18680.62 )
PDLI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -114.58   Max: 673927.45
Current: 18680.62

-114.58
673927.45
Revenue Growth (%) 12.90
PDLI's Revenue Growth (%) is ranked higher than
86% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. PDLI: 12.90 )
PDLI' s 10-Year Revenue Growth (%) Range
Min: -88.7   Max: 997.9
Current: 12.9

-88.7
997.9
EBITDA Growth (%) 35.50
PDLI's EBITDA Growth (%) is ranked higher than
95% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. PDLI: 35.50 )
PDLI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 853.4
Current: 35.5

0
853.4
EPS Growth (%) 48.20
PDLI's EPS Growth (%) is ranked higher than
96% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. PDLI: 48.20 )
PDLI' s 10-Year EPS Growth (%) Range
Min: -89.5   Max: 798.3
Current: 48.2

-89.5
798.3
» PDLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PDLI Guru Trades in Q4 2013

Steven Cohen 19,823 sh (New)
Paul Tudor Jones 94,400 sh (+226.64%)
Joel Greenblatt 3,343,973 sh (+15.69%)
Jim Simons 11,665,354 sh (+0.63%)
Jean-Marie Eveillard 2,800 sh (unchged)
Jeremy Grantham 42,543 sh (-10.64%)
John Hussman 1,087,000 sh (-50.99%)
» More
Q1 2014

PDLI Guru Trades in Q1 2014

Jim Simons 11,859,184 sh (+1.66%)
John Hussman 1,087,000 sh (unchged)
Jean-Marie Eveillard 2,800 sh (unchged)
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Paul Tudor Jones 82,400 sh (-12.71%)
Joel Greenblatt 1,665,543 sh (-50.19%)
» More
Q2 2014

PDLI Guru Trades in Q2 2014

Jim Simons 12,896,754 sh (+8.75%)
Jean-Marie Eveillard 2,800 sh (unchged)
John Hussman Sold Out
Paul Tudor Jones 50,600 sh (-38.59%)
Joel Greenblatt 789,804 sh (-52.58%)
» More
Q3 2014

PDLI Guru Trades in Q3 2014

Paul Tudor Jones 125,900 sh (+148.81%)
Jim Simons 13,745,892 sh (+6.58%)
Jean-Marie Eveillard 2,800 sh (unchged)
Joel Greenblatt 25,997 sh (-96.71%)
» More
» Details

Insider Trades

Latest Guru Trades with PDLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Reduce -96.71%0.09%$7.51 - $10.26 $ 8.25-11%25997
John Hussman 2014-06-30 Sold Out 0.68%$8 - $9.85 $ 8.25-7%0
Joel Greenblatt 2014-06-30 Reduce -52.58%0.11%$8 - $9.85 $ 8.25-7%789804
Joel Greenblatt 2014-03-31 Reduce -50.19%0.34%$7.46 - $9.14 $ 8.25-4%1665543
John Hussman 2013-12-31 Reduce -50.99%0.49%$7.59 - $10.1 $ 8.25-2%1087000
John Hussman 2013-09-30 Reduce -21.04%0.21%$7.72 - $8.44 $ 8.253%2218000
Joel Greenblatt 2013-09-30 Add 24.84%0.15%$7.72 - $8.44 $ 8.253%2890564
Joel Greenblatt 2013-03-31 Add 23.5%0.15%$6.65 - $7.53 $ 8.2516%2135460
Joel Greenblatt 2012-12-31 Add 561.89%0.59%$7.09 - $8.37 $ 8.256%1729133
John Hussman 2012-12-31 Add 20.19%0.09%$7.09 - $8.37 $ 8.256%3012000
John Hussman 2012-09-30 Add 176.91%0.29%$6.59 - $7.73 $ 8.2516%2506000
Seth Klarman 2012-03-31 Sold Out 1.5%$6.02 - $6.58 $ 8.2539%0
Joel Greenblatt 2012-03-31 Add 33.54%0.04%$6.02 - $6.58 $ 8.2539%270346
Seth Klarman 2011-12-31 Reduce -48.84%1.4%$5.35 - $6.4 $ 8.2538%8000000
Joel Greenblatt 2011-12-31 Add 31.29%0.04%$5.35 - $6.4 $ 8.2538%202444
George Soros 2011-12-31 Sold Out 0.001%$5.35 - $6.4 $ 8.2538%0
Seth Klarman 2011-09-30 Add 68.81%1.17%$5.47 - $6.39 $ 8.2540%15636000
John Hussman 2011-09-30 New Buy0.08%$5.47 - $6.39 $ 8.2540%905000
Joel Greenblatt 2011-09-30 Add 41.81%0.04%$5.47 - $6.39 $ 8.2540%154201
George Soros 2011-09-30 New Buy$5.47 - $6.39 $ 8.2540%10000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 4.20
PDLI's P/E(ttm) is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PDLI: 4.20 )
PDLI' s 10-Year P/E(ttm) Range
Min: 3.92   Max: 24.65
Current: 4.2

3.92
24.65
P/B 3.20
PDLI's P/B is ranked higher than
83% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. PDLI: 3.20 )
PDLI' s 10-Year P/B Range
Min: 1.6   Max: 38.49
Current: 3.2

1.6
38.49
P/S 2.40
PDLI's P/S is ranked higher than
95% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. PDLI: 2.40 )
PDLI' s 10-Year P/S Range
Min: 2.26   Max: 23.98
Current: 2.4

2.26
23.98
EV-to-EBIT 2.88
PDLI's EV-to-EBIT is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PDLI: 2.88 )
PDLI' s 10-Year EV-to-EBIT Range
Min: -148.8   Max: 43.9
Current: 2.88

-148.8
43.9
PEG 0.21
PDLI's PEG is ranked higher than
100% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PDLI: 0.21 )
PDLI' s 10-Year PEG Range
Min: 0.09   Max: 0.5
Current: 0.21

0.09
0.5
Shiller P/E 6.00
PDLI's Shiller P/E is ranked higher than
100% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PDLI: 6.00 )
PDLI' s 10-Year Shiller P/E Range
Min: 5.6   Max: 105.83
Current: 6

5.6
105.83
Current Ratio 1.31
PDLI's Current Ratio is ranked higher than
53% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. PDLI: 1.31 )
PDLI' s 10-Year Current Ratio Range
Min: 0.26   Max: 76.07
Current: 1.31

0.26
76.07
Quick Ratio 1.31
PDLI's Quick Ratio is ranked higher than
56% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. PDLI: 1.31 )
PDLI' s 10-Year Quick Ratio Range
Min: 0.26   Max: 76.07
Current: 1.31

0.26
76.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 7.40
PDLI's Dividend Yield is ranked higher than
98% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. PDLI: 7.40 )
PDLI' s 10-Year Dividend Yield Range
Min: 2.26   Max: 9.98
Current: 7.4

2.26
9.98
Dividend Payout 0.30
PDLI's Dividend Payout is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PDLI: 0.30 )
PDLI' s 10-Year Dividend Payout Range
Min: 0.24   Max: 0.6
Current: 0.3

0.24
0.6
Yield on cost (5-Year) 7.30
PDLI's Yield on cost (5-Year) is ranked higher than
97% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. PDLI: 7.30 )
PDLI' s 10-Year Yield on cost (5-Year) Range
Min: 2.26   Max: 9.98
Current: 7.3

2.26
9.98
Share Buyback Rate 3.80
PDLI's Share Buyback Rate is ranked higher than
98% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. PDLI: 3.80 )
PDLI' s 10-Year Share Buyback Rate Range
Min: 89.4   Max: -958.2
Current: 3.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.18
PDLI's Price/Tangible Book is ranked higher than
74% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. PDLI: 8.18 )
PDLI' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 47.2
Current: 8.18

0.9
47.2
Price/DCF (Projected) 0.94
PDLI's Price/DCF (Projected) is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PDLI: 0.94 )
PDLI' s 10-Year Price/DCF (Projected) Range
Min: 0.88   Max: 90.83
Current: 0.94

0.88
90.83
Price/Median PS Value 0.63
PDLI's Price/Median PS Value is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. PDLI: 0.63 )
PDLI' s 10-Year Price/Median PS Value Range
Min: 0.59   Max: 24.62
Current: 0.63

0.59
24.62
Price/Peter Lynch Fair Value 0.19
PDLI's Price/Peter Lynch Fair Value is ranked higher than
100% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PDLI: 0.19 )
PDLI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.18   Max: 2.65
Current: 0.19

0.18
2.65
Price/Graham Number 1.20
PDLI's Price/Graham Number is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PDLI: 1.20 )
PDLI' s 10-Year Price/Graham Number Range
Min: 1.12   Max: 117.29
Current: 1.2

1.12
117.29
Earnings Yield (Greenblatt) 34.70
PDLI's Earnings Yield (Greenblatt) is ranked higher than
98% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. PDLI: 34.70 )
PDLI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 35.6
Current: 34.7

2.3
35.6
Forward Rate of Return (Yacktman) 26.89
PDLI's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. PDLI: 26.89 )
PDLI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.8   Max: 64.1
Current: 26.89

-10.8
64.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PDL.Germany
PDL BioPharma, Inc., was organized as a Delaware corporation in 1986 under the name Protein Design Labs, Inc. In 2006, the Company changed its name to PDL BioPharma, Inc. The Company is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. The Company focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. It manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. patents, covers among other things, humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies and methods of producing humanized antibodies. It's U.S. Patent; covers methods and materials used in the manufacture of humanized antibodies. The Company entered into licensing agreements under Queen et al. patents with entities that are independently developing or have developed humanized antibodies. The Company entered into patents license agreement with Genentech, Biogen Idec and Chugai; and it entered into a royalty purchase and sale agreement with Depomed, Inc. As on year ended December 31, 2013, the Company received Queen et al. patent royalties on sales of the eight humanized antibody products, all of which are currently approved for use by the FDA and other regulatory agencies outside the United States; including, Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri and Actemra. The Company has also entered into licensing agreements under which it has licensed certain rights for development stage products that have not yet reached commercialization including products that are currently in Phase 3 clinical trials. The Company faces competition from other royalty buyers and enterprises. The Company's licensees, borrowers and royalty-agreement counterparties are subject to stringent regulation with respect to product safety and efficacy by various international, federal, state and local authorities.
» More Articles for PDLI

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against PDL BioPharma, Oct 17 2014 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against PDL BioPharma Inc Oct 15 2014 
Hot Picks with High Yields Jul 23 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
comment on PDLI May 12 2013 
My 4 Favorites From The 20 Cheapest Healthcare Dividend Stock List May 02 2013 
FV 22 MSN 10 Apr 19 2013 
68 Top-Yielding Stocks with Ex-Dividend Date in March 2013 Feb 27 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
comment on PDLI Nov 13 2012 

More From Other Websites
PDL BIOPHARMA, INC. Financials Nov 19 2014
PDL BIOPHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 19 2014
PDL BIOPHARMA, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Other... Nov 18 2014
PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics Nov 18 2014
PDL BIOPHARMA 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney... Nov 14 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in PDL... Nov 14 2014
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against PDL BioPharma... Nov 14 2014
PDL BIOPHARMA, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Other... Nov 14 2014
PDL BioPharma Announces Successful Conclusion of Revenue Interest Agreement with AxoGen Nov 14 2014
PDL BioPharma Announces Successful Conclusion of Revenue Interest Agreement with AxoGen Nov 14 2014
10-Q for PDL BioPharma, Inc. Nov 12 2014
PDL BioPharma to Present at Jefferies 2014 Global Healthcare Conference Nov 12 2014
PDL BioPharma to Present at Jefferies 2014 Global Healthcare Conference Nov 12 2014
EQUITY ALERT: Rosen Law Firm Reminds PDL BioPharma, Inc. Investors of Important November 17, 2014... Nov 11 2014
PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y Nov 11 2014
PDL BioPharma posts 3Q profit Nov 10 2014
PDL BioPharma posts 3Q profit Nov 10 2014
PDL BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Nov 10 2014
PDL BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2014
PDL BioPharma Announces Third Quarter 2014 and Year to Date Financial Results Nov 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK